Next Article in Journal
MicroRNA Markers of Previous Traumatic Brain Injury in Juvenile Offenders: Implications for Neuronal Dysfunction and Repair
Next Article in Special Issue
Next-Generation Sequencing Defines a Molecularly Confirmed ARPKD Core Within the Broader PKHD1-Associated Disease Spectrum
Previous Article in Journal
Hominin Variability and Evolutionary Relationships at Guattari Cave During the Middle and Late Pleistocene (San Felice Circeo, Latina, Italy)
Previous Article in Special Issue
Prenatal Exome Sequencing: When Does Diagnostic Yield Meet Clinical Utility?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Genes
Volume 17
Issue 2
10.3390/genes17020133
genes-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Molecular Profiling of Polish Pediatric Patients with Epilepsy: A Single-Center Diagnostic Experience Using Next-Generation Sequencing

by
Beata Chałupczyńska
1,
Elżbieta Ciara
1,*,
Paulina Halat-Wolska
1,
Agnieszka Pollak
2,
Piotr Stawiński
1,2,
Dorota Jurkiewicz
1,
Dorota Piekutowska-Abramczuk
1,
Marzena Gawlik
1,
Justyna Pietrasik
1,
Agata Cieślikowska
1,
Dorota Wicher
1,
Agata Ulatowska
3,
Dominika Jedlińska
3,
Julita Borkowska
3,
Dariusz Chmielewski
3,
Dorota Dunin-Wąsowicz
3,
Katarzyna Kotulska-Jóźwiak
3,
Krystyna Chrzanowska
1 and
Agnieszka Madej-Pilarczyk
1
1
Department of Medical Genetics, The Children’s Memorial Health Institute, Member of the European Reference Network ITHACA, 04-730 Warsaw, Poland
2
Department of Medical Genetics, Warsaw Medical University, 02-106 Warsaw, Poland
3
Department of Neurology and Epileptology, The Children’s Memorial Health Institute, Member of the European Reference Network EpiCARE, 04-730 Warsaw, Poland
*
Author to whom correspondence should be addressed.
Genes 2026, 17(2), 133; https://doi.org/10.3390/genes17020133
Submission received: 30 November 2025 / Revised: 18 December 2025 / Accepted: 19 January 2026 / Published: 27 January 2026
(This article belongs to the Special Issue Next-Generation Sequencing in Rare Genetic Diseases)
Browse Figures
Versions Notes

Abstract

Introduction: Epilepsy syndromes show marked clinical and genetic heterogeneity, with numerous functionally diverse genes involved in their etiology. Next-generation sequencing (NGS) has facilitated the identification of many monogenic epilepsy syndromes and enables earlier, more accurate diagnosis in pediatric patients. Materials and Methods: This study analyzes the molecular profiles of 87 pediatric patients with various forms of epilepsy in whom pathogenic or likely pathogenic variants were identified. Next-generation sequencing (NGS) using multi-gene epilepsy panels or whole-exome sequencing (WES) was performed. Results: A total of 88 pathogenic or likely pathogenic variants were detected in 48 epilepsy-related genes; 30 variants occurred de novo. SCN1A and KCNQ2 were the most frequent contributors (12.6% and 9.2%, respectively). The highest percentage of positive diagnoses (48%) was observed in patients with developmental and epileptic encephalopathy (DEE), with variants identified in genes including ALG13, ATP1A2, CACNA1A, CDKL5, CHD2, GABRG2, ITPA, KCNQ2, PCDH19, SCN1A, SCN2A, SCN3A, SCN8A, SMC1A, SPTAN1, STXBP1, and UBA5. Pathogenic variants in ANKRD11 were found in four patients with KBG syndrome, while other genes appeared sporadically. Conclusions: Targeted massively parallel sequencing is an effective diagnostic tool for pediatric epilepsy. The presence of numerous single-case findings highlights the high genetic heterogeneity of epilepsy. This approach enabled more precise diagnoses that would not have been achieved through clinical evaluation alone, underscoring the importance of genetic testing for prognosis and treatment planning in pediatric patients with unexplained epilepsy.

1. Introduction

Epilepsy is a common chronic disorder of the central nervous system and one of the most frequent complex neurological conditions in childhood. Its incidence shows a distinctly age-dependent pattern, with the highest rates observed during the first year of life, underscoring the importance of pediatric epilepsy as a critical area of focus in clinical care. Epilepsy arises from heterogeneous etiologies, including genetic: structural, metabolic, immune and non-genetic external/secondary epilepsies: infectious, stroke, traumatic brain injury and unknown causes. In nearly half of all cases no definitive etiology can be identified. Nevertheless, a substantial proportion of childhood-onset epilepsy have a genetic basis [1,2,3], and it is estimated that up to 40% of patients with severe epilepsy have a single-gene etiology [4].
The genetic background of epilepsy is highly complex, encompassing both monogenic and polygenic forms. Single-gene variants are widely recognized as a predominant pathogenic mechanism underlying many genetic epilepsies. With expanding knowledge of seizure pathophysiology, the number of genes implicated in monogenic epilepsy continues to grow rapidly. Currently, according to the OMIM database, 111 genes are associated with the DEE phenotype. These DEE-associated genes are listed in Supplementary Table S1. At the same time, molecular genetic testing has revealed not only extensive genetic heterogeneity within specific epilepsy syndromes but also marked phenotypic pleiotropy, whereby alterations in the same gene can lead to a broad range of epileptic and neurodevelopmental manifestations [5]. Childhood monogenic epilepsies associated with developmental delay therefore represent a wide spectrum of disorders involving diverse biological pathways—from ion channels and receptors to genes regulating cellular metabolism and signaling.
Advances in high-throughput sequencing technologies, particularly next-generation sequencing (NGS), have substantially expanded our ability to detect pathogenic variants and have become a cornerstone of clinical diagnostics of rare diseases. NGS-based approaches, such as targeted multigene panels and exome sequencing, enable the rapid identification of disease-causing variants, especially in patients with early-onset, treatment-resistant seizures and additional comorbidities. However, large-scale sequencing also generates extensive datasets that often include variants of uncertain significance, complicating clinical interpretation and underscoring the need for further refinement of molecular diagnostic strategies.
Integrating clinical and genetic data is crucial for understanding disease mechanisms, improving diagnostic accuracy, identifying novel pathogenic genes or biomarkers, and expanding the known genetic spectrum of epilepsy. Such integration also facilitates prediction of disease trajectory and prognosis through longitudinal follow-up and supports the development of precision medicine strategies tailored to specific genetic etiologies. Establishing an accurate molecular diagnosis as early as possible is essential for prognosis and appropriate counseling, and in monogenic epilepsies may also guide the selection of individualized therapeutic interventions targeting the underlying disease mechanism. Because the nature of the molecular defect directly influences both disease severity and therapeutic options, identifying the exact pathogenic variant, rather than only the affected gene, is critical for effective clinical management [6].
In this context, the present study evaluated 87 pediatric patients with epilepsy using NGS-based diagnostic methods, with the aim of identifying pathogenic or likely pathogenic variants, characterizing their clinical features, and assessing the effectiveness as well as the current limitations of molecular diagnostic strategies in pediatric epilepsy.

2. Materials and Methods

2.1. Patients

The study group consisted of 87 Polish patients with unexplained pediatric-onset epilepsy, referred to the Department of Medical Genetics of the Children’s Memorial Health Institute (CMHI) between April 2015 and May 2025. Structured clinical information was collected using a standardized form completed by the referring clinician or extracted from the medical records. Only patients under 18 years of age were eligible for inclusion. To classify each patient’s epilepsy, the following categories were considered: age at seizure onset, seizure type, suspected epileptic encephalopathy, suspected Dravet syndrome, refractory seizures, suspected channelopathy/receptoropathy, suspected metabolic epilepsy, structural brain anomalies and intellectual disability (ID)/developmental delay (DD). All participants or their legal guardians provided written informed consent to genetic analysis and participation in the study. The project was approved by the institutional bioethics committee.

2.2. Genetic Testing and Data Analysis

Genetic testing in all 87 individuals was performed using genomic DNA automatically extracted from peripheral blood leukocytes with either a MagNA Pure LC 2.0 (Roche Diagnostics, Risch-Rotkreuz, Switzerland) or a MagCore Nucleic Acid Extractor HF16Plus (RBC Bioscience, New Taipei City, Taiwan), according to the manufacturer’s protocol.

2.2.1. Next-Generation Sequencing and Variant Interpretation

About 50 ng of high-quality genomic DNA was used for next-generation sequencing (NGS). NGS was performed using either the original CMHI sequencing panel (CMHI1000) of over 1000 clinically relevant genes (Twist Bioscience, San Francisco, CA, USA) (Supplementary Table S2), TruSight One (TSO) sequencing panel (Illumina, San Diego, CA, USA), or whole exome sequencing (WES), constructed with the Twist Human Core Exome + Human RefSeq Panel kit (Twist Bioscience, San Francisco, CA, USA) to covering 99% of the protein-coding genes. Libraries were sequenced on the NovaSeq 6000 system (Illumina, San Diego, CA, USA) according to the manufacturer’s protocol. The average read depth was 129, with over 95% of the target regions covered at a minimum depth of 20-fold. The ‘Fold 80 base penalty’ parameter was used to assess coverage uniformity, and its average value is 1.28.
The most recent version of the epilepsy gene panel included 776 genes associated with developmental and epileptic encephalopathy and other epileptic syndromes (Supplementary Table S1) and was used as the primary test. Over the 10-year recruitment period, the panel was regularly updated to incorporate newly identified epilepsy-associated genes based on current information from Online Mendelian Inheritance in Man (OMIM, https://www.omim.org/ (accessed on 18 January 2026)), Human Gene Mutation Database (HGMD, http://www.hgmd.cf.ac.uk (accessed on 18 January 2026)), Clinical Genome Resource (ClinGen, https://clinicalgenome.org/ (accessed on 18 January 2026)), Genomics England PanelApp (PanelApp, https://panelapp.genomicsengland.co.uk/ (accessed on 18 January 2026)), U.S. National Library of Medicine (PubMed, https://pubmed.ncbi.nlm.nih.gov/ (accessed on 18 January 2026)). Whole exome sequencing was applied as a second-line test in patients (P24, P56, P69, P76) who had a negative result (no disease causing variant detected) from the multi-gene panel and in whom a definitive molecular diagnosis was still sought. WES was also used as a first-line test in patients (P08, P35, P52, P53, P70, P72, P80) presenting with multiple manifestations, including neurodevelopmental disorders or atypical phenotype (as described chapter 4 of the Discussion).
Raw FASTQ reads were mapped to a slightly modified human genome assembly GRCh38/hg38. Variant calling was performed using GATK HaplotypeCaller, MuTect2, FreeBayes, and DeepVariant to maximize sensitivity for detecting single-nucleotide variants (SNVs), small insertions/deletions, and mosaic variants. Copy-number variant (CNV) analysis was conducted with CNVkit and Decon. Detailed information on the methodology has been published previously by P. Halat-Wolska et al. [7]. Alignments were visualized using the Integrative Genomics Viewer (IGV, https://igv.org/ (accessed on 18 January 2026)) [8].
Variant filtering criteria included allele frequency, in silico pathogenicity predictions, and the predicted effect and genomic location of the variant. Variant consequence annotation was performed using VEP [9]. Variants were further annotated using multiple repositories, including population frequency databases such as the Genome Aggregation Database (gnomAD v4.1.0, https://gnomad.broadinstitute.org (accessed on 18 January 2026)), and an in-house allele-frequency database representing the Polish population (POLdb), which contains data from more than 24,000 individuals suspected of having a rare genetic disease. Predicted impact on protein structure and function was assessed using machine learning meta-predictors (BayesDel, REVEL) and individual tools (AlphaMissense, CADD, EIGEN, FATHMM-MKL, MutationTaster, PolyPhen-2, SIFT). Variants occurring at splice sites were analyzed using SpliceAI, ADA, MaxEntScan, Pangolin and RF. In silico predictions were retrieved through the GeneBe (https://genebe.net/ (accessed on 18 January 2026)) and VarSome platforms (https://varsome.com/ (accessed on 18 January 2026)). Alamut VisualTM Plus software (https://www.sophiagenetics.com/platform/alamut-visual-plus/ (accessed on 18 January 2026)) was also used. Conservation was assessed using phyloP100 scores. The novelty of detected variants was evaluated using ClinVar (https://www.ncbi.nlm.nih.gov/clinvar (accessed on 18 January 2026)), the Leiden Open Variation Database (LOVD, https://www.lovd.nl/ (accessed on 18 January 2026)), and the Human Gene Mutation Database (HGMD, http://www.hgmd.cf.ac.uk (accessed on 18 January 2026)).
Variants were interpreted according to the guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) [7,10,11]. ACMG/AMP criteria were assigned using the GeneBe platform [12], followed by manual refinement of criteria that could not be processed automatically to ensure accurate pathogenicity classification. According to these criteria, benign and likely benign variants were excluded, and only pathogenic and likely pathogenic (P/LP) variants were retained for analysis. The present study summarizes the results of probands with identified P/LP variants. Patients harboring variants of uncertain significance (VUS) will undergo more detailed clinical and genetic evaluation in the coming years.

2.2.2. Sanger Sequencing

Variants considered (potentially) disease-causing were validated in probands and, when possible, segregated in available family members using bidirectional Sanger sequencing with the BigDye Terminator v3.1 Kit (Applied Biosystems, Waltham, MA, USA) on the ABI 3130 Genetic Analyzer (Applied Biosystems, Waltham, MA, USA), according to the manufacturer’s protocol. The nomenclature of molecular variants followed the Human Genome Variation Society (HGVS) guidelines (https://hgvs-nomenclature.org/ (accessed on 18 January 2026)) and was referenced to the MANE Select transcript [13], which is aligned with the GRCh38/hg38 human genome assembly.

3. Results

3.1. Clinical Characteristics of Patients

The study cohort consisted of 87 probands: 42 males (48.3%) and 45 females (51.7%) with epilepsy, developmental and epileptic encephalopathies (DEE), early-onset epilepsies, or syndromic neurodevelopmental disorders. Detailed clinical characteristics of the cohort are presented in Table 1.
In 45 cases, epilepsy began in the neonatal or early-infantile period, presenting with tonic–clonic, myoclonic, tonic, clonic, atonic, or febrile seizures, absence episodes, or infantile spasms (West syndrome). Generalized seizures were observed in 28 patients, while 11 experienced focal or multifocal seizures. Additionally, 5 patients had both generalized and focal seizures, in 48 patients the seizure type could not be determined. Global developmental delay or intellectual disability was present in 41 patients, motor disability in 33, and speech delay in 23. EEG abnormalities—such as epileptiform discharges, hypsarrhythmia, suppression–burst patterns, or other atypical findings—were documented in 36 patients. Drug-resistant seizures were noted in 27 individuals. MRI abnormalities were identified in 21 patients and included structural brain malformations (e.g., cerebellar hypoplasia, holoprosencephaly, polymicrogyria, schizencephaly), delayed myelination, and progressive cerebral atrophy. Epileptic seizures occurred as part of various genetic syndromes with dysmorphic features in 17 patients.
Neonatal-onset seizures were observed in 18 patients (20.7%). In most patients (n = 28), the first seizure episode occurred between 1 month and 1 year of age; in 12 patients between 1 and 5 years; and in 9 patients at ≥5 years of age. In 20 patients, seizure onset could not be determined (Figure 1A).

3.2. Molecular Findings and Genotyping

Among 87 patients tested with next-generation sequencing, 76 (87.4%) had only NGS panel (CMHI1000 or TSO) performed, and 7 (8%) underwent only whole exome sequencing. In 4 patients with negative result of panel sequencing, the analysis was expanded to whole exome (Table 1, Figure 1B). Sanger sequencing was used to verify variants in 40 probands (46%) (Figure 1B). Qualifying variants identified in the study group are listed in Supplementary Table S3.
The molecular profile of the study cohort is presented in Figure 1C. In total, 88 different variants were detected in 48 genes, of which variants affecting 10 genes (SCN1A, KCNQ2, ALDH7A1, ANKRD11, CHD2, PCDH19, SCN2A, STXBP1, SYNGAP1, UBA5) accounted for 48% (49/102) of all variants identified (Supplementary Table S4, Figure 1C). In addition, single individuals had variants identified in the following genes: ALG13, AMT, ATP1A3, CACNA1A, CDKL5, CLN6, COL4A1, CUL3, DEPDC5, DYNC1H1, GABRG2, GAMT, GRIN2A, ITPA, KANSL1, KCNJ10, KCTD7, KMT2A, MECP2, NHLRC1, NPC1, OPHN1, POMT2, PURA, SCN3A, SCN8A, SMARCB1, SMC1A, SPTAN1, TPP1, TSC1, TUBA1A, UPB1, and ZEB2. The causative genes in patients with neonatal-onset epilepsy included ALDH7A1, AMT, ATP1A3, COL4A1, GRIN2A, KCNQ2, PURA, SCN2A, SCN3A, and STXBP1, whereas in patients with seizure onset after 5 years of age, the causative genes included CACNA1A, DEPDC5, CLN6, DYNC1H1, NHLRC1, NPC1, SLC2A1, STXBP1, and ZEB2.
Among all detected variants, pathogenic or likely pathogenic single-nucleotide variants (SNVs) were found in 87 patients. There were 45 missense variants, 15 nonsense variants, 11 frameshift deletions, 7 frameshift duplications, 7 splicing alterations, and single occurrences of a frameshift indel, an in-frame deletion, and an in-frame duplication (Figure 1E).
Family segregation was carried out in 41 probands, identifying two parents with symptomatic autosomal dominant epilepsy (P07, P40). Autosomal dominant (AD) conditions were identified in 70.1% of patients (61/87). In this group, 28.7% (25/87) had de novo pathogenic or likely pathogenic (P/LP) variants, while 2.3% (2/87) inherited variants from an affected heterozygous parent (Table 1). Autosomal recessive (AR) conditions were diagnosed in 15 patients (15/87). X-linked (XL) conditions were identified in 12.6% (11/87), including 4 de novo variants, 1 hemizygous variant in OPHN1 inherited from an unaffected heterozygous mother, and 1 heterozygous variant in PCDH19 inherited from an unaffected hemizygous father, consistent with the specific X-linked inheritance pattern. In total, among all 88 variants identified, 12% were of parental origin, whereas 35% occurred de novo. In 46 cases (53%), segregation studies could not be performed (Figure 1D). In these instances, parental samples were not available, either because the families did not present for sample collection, exercised their right to refuse genetic testing or attempts to contact them were unsuccessful.
Among the identified variants, 64 had been previously reported in databases such as ClinVar, HGMD, or LOVD, while 24 were novel (Figure 1F). According to ACMG/AMP criteria, 18 variants were classified as pathogenic (P) and 6 as likely pathogenic (LP). Sixteen of the newly identified variants were loss-of-function (LoF) and thus met the PVS1 criterion. Eight variants were missense changes, five of which occurred de novo (PM6). For one missense variant, c.3789C>A in SCN1A (P03), segregation analysis in the parents was not performed. However, within this hotspot region, eight amino acids have pathogenic missense changes in a ±8 amino-acid window around the variant, and another nucleotide change resulting in the same amino acid substitution has previously been reported as likely pathogenic in ClinVar, supporting criteria PS1, PM1, and PM2.
We identified 11 novel molecular variants classified as P/LP according to the ACMG criteria: ANKRD11: c.1442C>A and c.6191_6192del, CHD2: c.4797_4798dupCA, COL4A1: c.4031G>A, PURA: c.885delinsGC, SCN1A: c.752T>A and c.2468A>T, SCN8A: c.2895C>A, SMARCB1: c.919T>C, SMC1A: c.3061dup, WDR45: c.103G>T (Supplementary Table S3). Five variants were recurrent: ALDH7A1: c.328C>T, KCNQ2: c.1678C>T, PRRT2: c.649dup, STXBP1: c.1162C>T, UBA5: c.796G>C; each identified in two unrelated probands. Given this limited number of observations, it is not possible to reliably assess a potential founder effect. These variants should therefore be regarded as rare within our population, and the available data do not support a hypothesis of shared ancestry.
The ACMG/AMP classification for each individual variant is provided in the publicly available original GeneBe database and is also summarized in the column “Variant ACMG classifications” in Supplementary Table S3.
Analysis of the molecular background in our cohort enabled classification of epilepsies into four categories based on genetic pathomechanisms: channelopathies (variants in 7 genes; 26 patients), receptoropathies (variants in 2 genes; 2 patients), metabolic epilepsies (variants in 10 genes; 13 patients), and structural-genetic/developmental epilepsies (variants in 29 genes; 46 patients) (Table 2).

4. Discussion

Childhood and early-infantile epilepsy are characterized by marked genetic and molecular heterogeneity. In recent years, high-throughput technologies such as exome sequencing have revealed a large number of genes implicated in epileptogenesis, many of which contribute to extremely rare, individualized phenotypes. This molecular diversity limits the reliability of classification based solely on clinical presentation and necessitates a diagnostic approach focused on identifying the specific underlying genetic cause. In our study group, the identified variants correlated with the symptoms observed in probands. The majority of patients had concomitant neurodevelopmental disorders, which were frequent in patients with developmental and epileptic encephalopathy (DEE) or epilepsy with intellectual disability/developmental delay (ID/DD) (48%, 42/87 and 47%, 41/87, respectively).
The most common type of seizure was generalized, observed in 32% (28/87) of patients, whereas nocturnal seizures were detected in 3.5% (3/87). However, in many cases, it was difficult to determine the type of seizure, and therefore the type of epilepsy was not classified in 24 patients (27.6%). Refractory seizures were observed in 31% (27/87) of patients. MRI abnormalities were detected in 24.1% (21/87) of patients, although the performance of MRI scans was documented in only 47% (41/87) of cases. According to current guidelines, brain imaging is recommended for all children with epilepsy [14]. EEG abnormalities were present in 41.4% (36/87) of patients. Additionally, epilepsy associated with metabolic disorders was detected in 13 patients (14.9%). In 42 patients, a diagnosis of DEE was confirmed through genetic testing. The most frequent causative gene, found in 12.6% (11/87) of patients, was SCN1A, known to be associated with both DEE and Dravet syndrome. The diagnostic yield was highest in patients with a more severe disease course, earlier age of onset, DEE diagnosis, or concomitant intellectual disability or motor impairment [15,16,17]. According to previous studies, the diagnostic yield for DEE is expected to reach 32% [15]. Similar results were obtained in another Polish study on the genetic background of epilepsy [18], in which the highest rate of positive diagnoses applied to children with ID/DD and generalized or generalized/focal onset seizures (41%) and in children with DEEs (40%). These results indicate that ID/DD is the main factor influencing the percentage of positive epilepsy diagnoses.
It should be emphasized that an accurate assessment of diagnostic yield requires the inclusion of all tested individuals, including patients with both positive and negative results. In the present study, diagnostic yield was therefore not evaluated, as the analysis was limited to patients harboring pathogenic or likely pathogenic (P/LP) variants, while cases with negative or inconclusive results, including variants of uncertain significance (VUS), were excluded. Consequently, the findings presented here should not be interpreted as a measure of diagnostic yield, but rather as an indication of the utility of the applied gene panels in identifying pathogenic variants associated with developmental and epileptic encephalopathies (DEE).
In 11 patients with clinically suspected Dravet syndrome (DS), a confirmatory pathogenic or likely pathogenic variant in the SCN1A gene was identified in 7 patients. The remaining 4 patients had variants in the following genes: ATP1A3 (associated with developmental and epileptic encephalopathy 99), KMT2A (associated with Wiedemann-Steiner syndrome), PCDH19 (associated with developmental and epileptic encephalopathy 9), and SYNGAP1 (associated with intellectual developmental disorder, autosomal dominant 5). This indicates that an initial clinical diagnosis of Dravet syndrome is not always associated with SCN1A gene alterations. Dravet syndrome may initially manifest as febrile seizures; while 70–80% of patients with DS have SCN1A loss-of-function (LoF) variants, Dravet-like phenotypes can also result from pathogenic variants in other genes, including CHD2, GABRA1, GABRG2, SCN1B, SCN2A, SCN8A, PCDH19, and STXBP1 [19]. In a study by JM de Sainte Agathe, 29% of individuals carrying SCN1A LoF variants had not been clinically classified as having DS, which was an unexpected finding. In that cohort, 58% of patients were below 2 years old at the time of first presentation, rendering a diagnosis of intellectual disability premature. Conversely, several patients with a clinical diagnosis of DS were ultimately found to carry pathogenic variants in genes more frequently associated with other phenotypes. This likely reflects the high prevalence of febrile seizures outside the Dravet syndrome/generalized epilepsy with febrile seizures plus (GEFS+) spectrum. Notably, febrile triggers were observed in 30% of DEE cases, while the DS spectrum accounted for only 10% of the DEE cohort [20].
Among four patients with atypical clinical presentations of DEE, patient P06 had a homozygous variant c.520T>C p.(Trp174Arg) in the GAMT gene, typically associated with cerebral creatine deficiency syndrome 2 (MIM #612736); patient P24 had a de novo hemizygous variant c.103G>T p.(Glu35*) in WDR45, associated with neurodegeneration with brain iron accumulation 5 (MIM #300894); patient P81 had a homozygous variant c.179T>C p.(Ile60Thr) in KCNJ10, associated with SESAME syndrome (MIM #612780); and patient P83 carried a novel de novo variant c.885delinsGC p.(His296Profs*21) in PURA, associated with neurodevelopmental disorder with neonatal respiratory insufficiency, hypotonia, and feeding difficulties (MIM #616158). Since variants in these genes are not typical causes of DEE, these cases highlight the difficulty in distinguishing seizure-accompanied ID or developmental delay from true DEE, in which ID results partly from uncontrolled epileptic activity [21].
In nine other patients with an unidentified epilepsy phenotype, genetic testing enabled the diagnosis of known syndromic genetic disorders associated with the following genes: ANKRD11 (KBG syndrome) in four patients, KANSL1 (Koolen-De Vries syndrome), KMT2A (Wiedemann-Steiner syndrome), MECP2 (Rett syndrome), OPHN1 (X-linked syndromic intellectual developmental disorder, Billuart type), SMARCB1 (Coffin-Siris syndrome 3), and ZEB2 (Mowat–Wilson syndrome). Syndromic epilepsies are characterized by substantial phenotypic heterogeneity, including dysmorphic features, multisystem involvement, and neurodevelopmental impairments. Consequently, traditional clinical criteria used to differentiate these conditions have limited specificity and stability, particularly in children aged 1–6 years. The clinical presentation of many syndromic forms evolves over time, further reducing the reliability of phenotype-based classification. In these patients, a “genotype-first” diagnostic approach has proven particularly valuable.
Four patients underwent multiple genetic tests and received a diagnosis only after WES. The molecular changes involved the following genes: UBA5, UPB1, and WDR45. Using WES as a first-line diagnostic tool could allow molecular diagnoses in some cases. For example, patients P56 and P76, who presented with epilepsy and severe neurological symptoms, were found to carry variants in UBA5 following a negative CMHI1000 panel result: a novel c.796G>C p.(Val266Leu) variant, and two other variants in trans: a novel c.698T>A p.(Leu233His) and a known c.1111G>A p.(Ala371Thr). The UBA5 gene is associated with developmental and epileptic encephalopathy 44. Previous Polish studies confirm the high effectiveness of dedicated epilepsy panels [18]. According to the National Society of Genetic Counselors, multi-gene panels should include a minimum of 25 genes [22]. Literature suggests that a “basic” panel of 30 genes accounts for most diagnoses, while larger panels contribute only marginally to additional findings. Moreover, evaluating the diagnostic yield of genetic tests requires careful cohort selection (e.g., childhood vs. adult epilepsy, focal epilepsy, DEE, metabolic or structural epilepsy) [23].
In the study by Krygier et al., only 5 of 127 patients were diagnosed using WES, while 41 were diagnosed using a gene panel [18]. Of 16 patients who underwent WES after a negative CMHI1000/TSO panel, only one yielded a molecular diagnosis. Krey et al. highlighted the potential for precision therapy based on variants in genes: ALDH7A1, PNPO, PLPBP, CAD, CHRNA2, CHRNA4, CHRNB2, GRIN2A, GRIN2B, GRIN2D, KCNA2, KCNQ2, KCNQ3, SCN1A, SCN2A, SCN8A, SLC2A1, TSC1, TSC2 [24]. Fifteen of these genes are included in the CMHI1000 panel used in our study.
Interestingly, among four patients with PCDH19 variants, one male patient (P59) presented with DEE and Klinefelter syndrome (47, XXY). To date, only one patient with this combination has been reported [25]. PCDH19-clustering epilepsy (PCDH19-CE) is an X-linked DEE characterized by clusters of focal or generalized seizures, typically beginning between 6 and 36 months of age, often triggered by febrile or afebrile illnesses, and associated with a wide spectrum of neuropsychiatric features. The “cellular interference” mechanism explains why heterozygous females and mosaic males are affected, while hemizygous males are usually spared, resulting in considerable phenotypic variability that does not consistently correlate with variant type [25,26,27,28,29,30,31,32,33,34,35]. In our cohort, we describe four patients with PCDH19-CE, including one boy with Klinefelter syndrome, who had drug-resistant febrile and generalized tonic–clonic seizures starting at 2.5 years, psychomotor and speech delay, and normal MRI findings. A heterozygous c.2452C>T p.(Gln818*) variant in PCDH19 was identified. Three additional female patients (P32, P43, P44) exhibited variable phenotypes, ranging from drug-resistant early-onset seizures with developmental delay to milder epilepsy without cognitive impairment. These cases highlight that disease severity is influenced more by mosaicism and age at seizure onset than by variant type, emphasizing the challenges of predicting outcomes based solely on molecular findings.
Genotype–phenotype correlations suggest that objective clinical data may be more predictive than classification into specific epilepsy syndromes [20]. Thorough phenotypic characterization, including MRI and biochemical tests, is critical. In patients with seizure onset before one year of age, who constituted the majority of our cohort, the phenotype may be incomplete, and early genetic diagnosis could enable targeted therapy. Our findings confirm that clinical symptoms and genetic etiology do not always align.
Among epilepsies with a confirmed genetic basis, many are monogenic disorders with autosomal dominant inheritance; however, a substantial proportion of variants arise de novo [36]. Metabolic epilepsies are most frequently associated with autosomal recessive defects [37]. In our study, autosomal dominant conditions were identified in 70.1% of patients, autosomal recessive in 17.2%, and X-linked in 12.6%. This is broadly consistent with Lindy et al., where ~75% of positive cases carried P/LP variants in AD genes and 18.2% in XL genes [38], though our cohort showed a higher proportion of AR inheritance. Missense variants were the most common type of SNV (51%), followed by nonsense (17%), frameshift deletions (13%), frameshift duplications (8%), splicing alterations (8%), frameshift indels (1%), in-frame deletions (1%), and in-frame duplications (1%) (Figure 1E). We identified 24 novel variants, including 16 LoF (66.7%) and 8 missense variants (33.3%).
Consistent with numerous studies across diverse populations, our data confirm that, despite substantial genetic heterogeneity, a limited number of genes account for a large proportion of pediatric epilepsy cases. Large cohort and gene panel–based studies from Europe, North America, and Asia have repeatedly demonstrated that a small group of genes dominates the etiology of pediatric epilepsies. Frequently implicated genes include SCN1A, SCN2A, KCNQ2, STXBP1, PCDH19, and CDKL5, as well as several genes encoding GABA receptor subunits. Together, these genes account for a substantial proportion of early-onset epileptic encephalopathies and primary channelopathies, making them key diagnostic targets [15,18,38,39,40,41,42,43].
In our cohort, 48% of molecular diagnoses involved the ten most frequently identified genes: SCN1A (n = 11), KCNQ2 (n = 8), ALDH7A1 (n = 4), ANKRD11 (n = 4), CHD2 (n = 4), PCDH19 (n = 4), STXBP1 (n = 4), UBA5 (n = 4), SCN2A (n = 3), and SYNGAP1 (n = 3), which the numbers in parentheses indicate the number of affected alleles identified for each gene. This distribution reflects the predominant contribution of sodium channel and synaptic genes reported in population-based studies from both Western and Asian cohorts [38,43,44]. Notably, in the study by Lindy et al., more than 80% of diagnoses were attributable to the seven most frequently implicated genes [38].
The recurrent identification of PCDH19, CHD2, SYNGAP1, and STXBP1 in our cohort is consistent with findings from large diagnostic series demonstrating their significant contribution to developmental and epileptic encephalopathies [38,45,46]. Similar gene distributions have been reported in other studies, including ANKRD11, CHD2, PCDH19, and STXBP1 [15], as well as SCN1A, KCNQ2, and PCDH19 [47]. The prominence of SCN1A variants in our patients aligns with previous pediatric studies identifying this gene as the most common cause of genetic epilepsies, particularly Dravet syndrome and related phenotypes [6,15,38,39]. In the study by Krygier et al., PCDH19 and STXBP1 were among the most frequently identified genes alongside SCN1A [18], whereas ALDH7A1 and KCNQ2 were also prominent in the cohort reported by Andjelkovic et al. [6]. The presence of ALDH7A1 among the more frequently identified genes in our cohort further aligns with reports highlighting its role in early-onset and potentially treatable epilepsies across different populations [18,48].
Most identified variants were unique. Only eight genes were detected in more than two individuals. However, six recurrent variants were observed among unrelated probands, including c.649dupC in PRRT2, which has also been reported as the most common recurrent variant in multiple independent studies [20,38,49]. Despite these recurrent variants, none were dominant, reflecting the high genetic variability characteristic of childhood epilepsy. This pattern aligns with observations from multiple populations [50,51,52].
Overall, the genetic architecture observed in the Polish cohort closely parallels that reported in global population-based studies. Minor differences in gene frequencies are likely attributable to cohort composition, age at seizure onset, and referral patterns rather than population-specific effects. These findings underscore that established epilepsy-associated genes constitute robust diagnostic targets across diverse populations. Despite these recurrent variants, none were dominant, reflecting the high genetic variability characteristic of childhood epilepsy. This pattern aligns with observations from multiple populations [50,51,52]. Our data confirm that epilepsy is a multigenic and multifactorial disorder, where a single epileptic syndrome may involve multiple pathogenic events and may be classified into more than one seizure type or etiological category. Consequently, it is reasonable to classify epilepsy based on the molecular pathomechanism of the causative gene. In this study, genes were categorized according to the function of the encoded protein: channelopathies, receptoropathies, metabolic, and structural/developmental. The largest group comprised structural/developmental genes (29 genes in 52.9% of patients). Ion channel gene variants represented a substantial functional category, affecting 29.9% of patients, although they accounted for only seven genes (14.6%). By comparison, Liu et al. reported ion channel gene variants as the largest functional category (55.8%) [53] while Henry O. et al. found ion channel genes as the most enriched group (24.8%) [49]. Our study confirms the high incidence of epilepsy during the first year of life (53%), consistent with previous reports [54]. Stodberg T et al. demonstrated that two-thirds of children with epilepsy onset in the first year of life can receive a specific diagnosis [14].
Next-generation sequencing (NGS) enabled molecular diagnoses regardless of structural or metabolic findings, substantially increasing diagnostic yield [14]. In our cohort, 68% of patients with known genetic etiologies had structural or metabolic abnormalities, a proportion higher than in previous studies. No significant differences were observed between patients with onset in the first year of life and those with later onset regarding the prevalence of structural/metabolic genetic disorders. A recent meta-analysis by Sheidley et al. (2022) reported a 19% diagnostic yield for multi-gene panels in epilepsy, with the highest yield observed in patients with DEE [23].
Genetic testing is essential in evaluating epilepsy, particularly in early-onset, severe, or treatment-resistant cases. Identifying a pathogenic variant provides a precise diagnosis, guiding prognosis, and potentially reducing the need for invasive or costly tests. A confirmed genetic result also informs counseling by clarifying inheritance patterns, recurrence risk, family planning and identifying at-risk relatives. Importantly, genetic findings increasingly guide therapy. Advances in epilepsy genetics have enabled a shift from empiric antiseizure medication selection (ASM) toward genetically driven and precision-based therapies. Genetic variation influences ASM efficacy and tolerability through effects on pharmacokinetics, pharmacodynamics, and adverse drug reactions, supporting the clinical utility of pharmacogenomics in epilepsy management [55]. Importantly, pathogenic variants in epilepsy-associated genes can directly guide drug choice. For example, gain-of-function mutations in sodium channel genes such as SCN2A or SCN8A may respond favorably to sodium channel blockers, whereas loss-of-function variants and SCN1A-related epilepsies often show poor response or seizure worsening with these agents, highlighting the need for genotype-guided pharmacotherapy [56]. Beyond tailored pharmacological treatment, gene-based therapies aim to address the underlying molecular cause of epilepsy. Gene therapy approaches include gene replacement, gene silencing, and modulation of neuronal excitability, most commonly using adeno-associated viral (AAV) vectors [57]. While these approaches hold considerable promise, challenges related to delivery, specificity, timing, and long-term safety remain, and continued translational research is required before widespread clinical implementation [58].

5. Conclusions

  • Our study confirms that next-generation sequencing (NGS), including both targeted gene panels and whole-exome sequencing (WES), is an effective and reliable diagnostic tool for pediatric epilepsy. These approaches substantially improve the detection of underlying genetic causes, facilitating more accurate clinical decision-making and enabling individualized therapeutic strategies.
  • Establishing an etiological diagnosis remains essential for accurate disease classification and for guiding both current and future pharmacological interventions.
  • The identification of novel genetic markers—both genes and variants—and their associated phenotypes expands the clinical and genetic spectrum of epilepsies, providing valuable insights into the pathomechanism of these disorders in children.
  • The molecular profile observed in our Polish pediatric cohort closely mirrors patterns reported in the literature, supporting the broader applicability and generalizability of our findings.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/genes17020133/s1.

Author Contributions

Conceptualization: B.C. and E.C. Methodology: B.C., E.C., A.P. and P.S. Software: P.S. Validation: E.C., A.P. and P.S. Formal analysis: B.C., E.C. and P.H.-W. Investigation: B.C., E.C., P.H.-W., A.P., D.J. (Dorota Jurkiewicz), D.P.-A. and M.G. Resources: E.C. Data curation: B.C., P.S., J.P., A.C., D.W., D.D.-W., K.K.-J., A.M.-P., A.U., D.J. (Dominika Jedlińska), J.B. and D.C. Writing—original draft preparation: B.C. Writing—review and editing: K.K.-J., E.C. and P.H.-W. Visualization: B.C. Supervision: A.M.-P., E.C. and K.C. Project administration: K.C. All authors have read and agreed to the published version of the manuscript.

Funding

The study was partially funding by the projects: CMHI M39/19, MEiN 7071/IB/SN/2020, MEiN 7088/II-KDM/SN/2020.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of The Children’s Memorial Health Institute (No. 29/KBE/2018; 10 October 2018).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study or parents/statutory representatives. Written informed consent has been obtained from the patients or parents/statutory representatives to publish this paper.

Data Availability Statement

The original contributions presented in this study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Acknowledgments

We gratefully acknowledge the support of the European Reference Networks ERN-ITHACA (European Reference Network for Rare Malformation Syndromes, Intellectual and Other Neurodevelopmental Disorders) and ERN-EpiCARE (European Reference Network for Rare and Complex Epilepsies). The affiliation of our center, the Children’s Memorial Health Institute (Warsaw, Poland), with these networks greatly facilitated patient recruitment, data collection, and the sharing of expertise across participating centers. We extend our sincere gratitude to Dorota Siestrzykowska for her invaluable support of the scientific work conducted at the Department of Medical Genetics, particularly for performing high-quality DNA isolations and for maintaining the highest standards in the biobanking of biological and genetic material. We also express our thanks to all clinicians from the Genetic Counseling Clinic and the Department of Neurology and Epileptology at the Children’s Memorial Health Institute in Warsaw for their contribution and collaboration.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Zhang, D.; Liu, X.; Deng, X. Genetic Basis of Pediatric Epilepsy Syndromes. Exp. Ther. Med. 2017, 13, 2129–2133. [Google Scholar] [CrossRef]
  2. Fisher, R.S.; Cross, J.H.; French, J.A.; Higurashi, N.; Hirsch, E.; Jansen, F.E.; Lagae, L.; Moshé, S.L.; Peltola, J.; Roulet Perez, E.; et al. Operational Classification of Seizure Types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017, 58, 522–530. [Google Scholar] [CrossRef] [PubMed]
  3. Sołowiej, E.; Sołowiej, W.; Blecharz-Klin, K. The Impact of Antiepileptic Drug Therapy on Oral Health in Children with Epilepsy: Current Evidence, Mechanisms, and Management Strategies. Prospect. Pharm. Sci. 2025. [Google Scholar] [CrossRef]
  4. Guerrini, R.; Balestrini, S.; Wirrell, E.C.; Walker, M.C. Monogenic Epilepsies: Disease Mechanisms, Clinical Phenotypes, and Targeted Therapies. Neurology 2021, 97, 817–831. [Google Scholar] [CrossRef]
  5. McTague, A.; Howell, K.B.; Cross, J.H.; Kurian, M.A.; Scheffer, I.E. The Genetic Landscape of the Epileptic Encephalopathies of Infancy and Childhood. Lancet Neurol. 2016, 15, 304–316. [Google Scholar] [CrossRef] [PubMed]
  6. Andjelkovic, M.; Klaassen, K.; Skakic, A.; Marjanovic, I.; Kravljanac, R.; Djordjevic, M.; Vucetic Tadic, B.; Kecman, B.; Pavlovic, S.; Stojiljkovic, M. Characterization of 13 Novel Genetic Variants in Genes Associated with Epilepsy: Implications for Targeted Therapeutic Strategies. Mol. Diagn. Ther. 2024, 28, 645–663. [Google Scholar] [CrossRef]
  7. Halat-Wolska, P.; Ciara, E.; Pac, M.; Obrycki, Ł.; Wicher, D.; Iwanicka-Pronicka, K.; Bielska, E.; Chałupczyńska, B.; Siestrzykowska, D.; Kostrzewa, G.; et al. Molecular Review of Suspected Alport Syndrome Patients—A Single-Centre Experience. Genes 2025, 16, 196. [Google Scholar] [CrossRef]
  8. Robinson, J.T.; Thorvaldsdóttir, H.; Winckler, W.; Guttman, M.; Lander, E.S.; Getz, G.; Mesirov, J.P. Integrative Genomics Viewer. Nat. Biotechnol. 2011, 29, 24–26. [Google Scholar] [CrossRef]
  9. McLaren, W.; Gil, L.; Hunt, S.E.; Riat, H.S.; Ritchie, G.R.S.; Thormann, A.; Flicek, P.; Cunningham, F. The Ensembl Variant Effect Predictor. Genome Biol. 2016, 17, 122. [Google Scholar] [CrossRef]
  10. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015, 17, 405–424. [Google Scholar] [CrossRef]
  11. Houge, G.; Laner, A.; Cirak, S.; de Leeuw, N.; Scheffer, H.; den Dunnen, J.T. Stepwise ABC System for Classification of Any Type of Genetic Variant. Eur. J. Hum. Genet. 2022, 30, 150–159. [Google Scholar] [CrossRef]
  12. Stawiński, P.; Płoski, R. Genebe.Net: Implementation and Validation of an Automatic ACMG Variant Pathogenicity Criteria Assignment. Clin. Genet. 2024, 106, 119–126. [Google Scholar] [CrossRef] [PubMed]
  13. Morales, J.; Pujar, S.; Loveland, J.E.; Astashyn, A.; Bennett, R.; Berry, A.; Cox, E.; Davidson, C.; Ermolaeva, O.; Farrell, C.M.; et al. A Joint NCBI and EMBL-EBI Transcript Set for Clinical Genomics and Research. Nature 2022, 604, 310–315. [Google Scholar] [CrossRef] [PubMed]
  14. Stödberg, T.; Tomson, T.; Barbaro, M.; Stranneheim, H.; Anderlid, B.; Carlsson, S.; Åmark, P.; Wedell, A. Epilepsy Syndromes, Etiologies, and the Use of Next-generation Sequencing in Epilepsy Presenting in the First 2 Years of Life: A Population-based Study. Epilepsia 2020, 61, 2486–2499. [Google Scholar] [CrossRef] [PubMed]
  15. Koh, H.Y.; Smith, L.; Wiltrout, K.N.; Podury, A.; Chourasia, N.; D’Gama, A.M.; Park, M.; Knight, D.; Sexton, E.L.; Koh, J.J.; et al. Utility of Exome Sequencing for Diagnosis in Unexplained Pediatric-Onset Epilepsy. JAMA Netw. Open 2023, 6, e2324380. [Google Scholar] [CrossRef]
  16. Zou, H.; Zhang, Q.; Liao, J.; Zou, D.; Hu, Z.; Li, B.; Chen, L.; Wen, J.; Zhao, X.; Zhang, V.W.; et al. Diagnostic Efficiency of Exome-Based Sequencing in Pediatric Patients with Epilepsy. Front. Genet. 2025, 15, 1496411. [Google Scholar] [CrossRef]
  17. Stefanski, A.; Calle-López, Y.; Leu, C.; Pérez-Palma, E.; Pestana-Knight, E.; Lal, D. Clinical Sequencing Yield in Epilepsy, Autism Spectrum Disorder, and Intellectual Disability: A Systematic Review and Meta-analysis. Epilepsia 2021, 62, 143–151. [Google Scholar] [CrossRef]
  18. Krygier, M.; Pietruszka, M.; Zawadzka, M.; Sawicka, A.; Lemska, A.; Limanówka, M.; Żurek, J.; Talaśka-Liczbik, W.; Mazurkiewicz-Bełdzińska, M. Next-Generation Sequencing Testing in Children with Epilepsy Reveals Novel Clinical, Diagnostic and Therapeutic Implications. Front. Genet. 2024, 14, 1300952. [Google Scholar] [CrossRef]
  19. Steel, D.; Symonds, J.D.; Zuberi, S.M.; Brunklaus, A. Dravet Syndrome and Its Mimics: Beyond SCN 1A. Epilepsia 2017, 58, 1807–1816. [Google Scholar] [CrossRef]
  20. De Sainte Agathe, J.; Monin, P.; Riccardi, F.; Nava, C.; Arnaud, L.; Mignot, C.; Ville, D.; Auvin, S.; Tardieu, S.; Larcher, K.; et al. The Clinical and Genetic Landscape of a French Multicenter Cohort of 2563 Epilepsy Patients Referred for Genetic Diagnosis. Eur. J. Neurol. 2025, 32, e70324. [Google Scholar] [CrossRef]
  21. Zuberi, S.M.; Wirrell, E.; Yozawitz, E.; Wilmshurst, J.M.; Specchio, N.; Riney, K.; Pressler, R.; Auvin, S.; Samia, P.; Hirsch, E.; et al. ILAE Classification and Definition of Epilepsy Syndromes with Onset in Neonates and Infants: Position Statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022, 63, 1349–1397. [Google Scholar] [CrossRef] [PubMed]
  22. Smith, L.; Malinowski, J.; Ceulemans, S.; Peck, K.; Walton, N.; Sheidley, B.R.; Lippa, N. Genetic Testing and Counseling for the Unexplained Epilepsies: An Evidence-based Practice Guideline of the National Society of Genetic Counselors. J. Genet. Couns. 2023, 32, 266–280. [Google Scholar] [CrossRef] [PubMed]
  23. Sheidley, B.R.; Malinowski, J.; Bergner, A.L.; Bier, L.; Gloss, D.S.; Mu, W.; Mulhern, M.M.; Partack, E.J.; Poduri, A. Genetic Testing for the Epilepsies: A Systematic Review. Epilepsia 2022, 63, 375–387. [Google Scholar] [CrossRef] [PubMed]
  24. Krey, I.; Platzer, K.; Esterhuizen, A.; Berkovic, S.F.; Helbig, I.; Hildebrand, M.S.; Lerche, H.; Lowenstein, D.; Møller, R.S.; Poduri, A.; et al. Current Practice in Diagnostic Genetic Testing of the Epilepsies. Epileptic Disord. 2022, 24, 765–786. [Google Scholar] [CrossRef]
  25. Romasko, E.J.; DeChene, E.T.; Balciuniene, J.; Akgumus, G.T.; Helbig, I.; Tarpinian, J.M.; Keena, B.A.; Vogiatzi, M.G.; Zackai, E.H.; Izumi, K.; et al. PCDH19-Related Epilepsy in a Male with Klinefelter Syndrome: Additional Evidence Supporting PCDH19 Cellular Interference Disease Mechanism. Epilepsy Res. 2018, 145, 89–92. [Google Scholar] [CrossRef]
  26. Kolc, K.L.; Sadleir, L.G.; Scheffer, I.E.; Ivancevic, A.; Roberts, R.; Pham, D.H.; Gecz, J. A Systematic Review and Meta-Analysis of 271 PCDH19-Variant Individuals Identifies Psychiatric Comorbidities, and Association of Seizure Onset and Disease Severity. Mol. Psychiatry 2019, 24, 241–251. [Google Scholar] [CrossRef]
  27. Kolc, K.L.; Sadleir, L.G.; Depienne, C.; Marini, C.; Scheffer, I.E.; Møller, R.S.; Trivisano, M.; Specchio, N.; Pham, D.; Kumar, R.; et al. A Standardized Patient-Centered Characterization of the Phenotypic Spectrum of PCDH19 Girls Clustering Epilepsy. Transl. Psychiatry 2020, 10, 127. [Google Scholar] [CrossRef]
  28. Kozina, A.A.; Okuneva, E.G.; Baryshnikova, N.V.; Fedonyuk, I.D.; Kholin, A.A.; Il’ina, E.S.; Krasnenko, A.Y.; Stetsenko, I.F.; Plotnikov, N.A.; Klimchuk, O.I.; et al. Two Novel PCDH19 Mutations in Russian Patients with Epilepsy with Intellectual Disability Limited to Females: A Case Report. BMC Med. Genet. 2020, 21, 209. [Google Scholar] [CrossRef]
  29. Trivisano, M.; Pietrafusa, N.; Terracciano, A.; Marini, C.; Mei, D.; Darra, F.; Accorsi, P.; Battaglia, D.; Caffi, L.; Canevini, M.P.; et al. Defining the Electroclinical Phenotype and Outcome of PCDH19-related Epilepsy: A Multicenter Study. Epilepsia 2018, 59, 2260–2271. [Google Scholar] [CrossRef]
  30. Kowkabi, S.; Yavarian, M.; Kaboodkhani, R.; Mohammadi, M.; Shervin Badv, R. PCDH19-Clustering Epilepsy, Pathophysiology and Clinical Significance. Epilepsy Behav. 2024, 154, 109730. [Google Scholar] [CrossRef]
  31. Depienne, C.; Trouillard, O.; Bouteiller, D.; Gourfinkel-An, I.; Poirier, K.; Rivier, F.; Berquin, P.; Nabbout, R.; Chaigne, D.; Steschenko, D.; et al. Mutations and Deletions in PCDH19 Account for Various Familial or Isolated Epilepsies in Females. Hum. Mutat. 2011, 32, E1959–E1975. [Google Scholar] [CrossRef] [PubMed]
  32. Zhou, W.; Ouyang, Y.; Ji, Y.; Xi, Q.; Zhao, L. Genetic Variants and Phenotype Analysis in a Five-Generation Chinese Pedigree with PCDH19 Female-Limited Epilepsy. Front. Neurol. 2023, 14, 1107904. [Google Scholar] [CrossRef] [PubMed]
  33. Shibata, M.; Ishii, A.; Goto, A.; Hirose, S. Comparative Characterization of PCDH19 Missense and Truncating Variants in PCDH19-Related Epilepsy. J. Hum. Genet. 2021, 66, 569–578. [Google Scholar] [CrossRef] [PubMed]
  34. Smith, L.; Singhal, N.; El Achkar, C.M.; Truglio, G.; Rosen Sheidley, B.; Sullivan, J.; Poduri, A. PCDH 19-related Epilepsy Is Associated with a Broad Neurodevelopmental Spectrum. Epilepsia 2018, 59, 679–689. [Google Scholar] [CrossRef]
  35. Chen, Y.; Yang, X.; Chen, J.; Yang, X.; Yang, Y.; Liu, A.; Zhang, X.; Wu, W.; Sun, D.; Yang, Z.; et al. PCDH19-Related Epilepsy in Mosaic Males: The Phenotypic Implication of Genotype and Variant Allele Frequency. Front. Neurol. 2022, 13, 1041509. [Google Scholar] [CrossRef]
  36. Oliver, K.L.; Scheffer, I.E.; Bennett, M.F.; Grinton, B.E.; Bahlo, M.; Berkovic, S.F. Genes4Epilepsy: An Epilepsy Gene Resource. Epilepsia 2023, 64, 1368–1375. [Google Scholar] [CrossRef]
  37. Sharma, S.; Prasad, A. Inborn Errors of Metabolism and Epilepsy: Current Understanding, Diagnosis, and Treatment Approaches. Int. J. Mol. Sci. 2017, 18, 1384. [Google Scholar] [CrossRef]
  38. Lindy, A.S.; Stosser, M.B.; Butler, E.; Downtain-Pickersgill, C.; Shanmugham, A.; Retterer, K.; Brandt, T.; Richard, G.; McKnight, D.A. Diagnostic Outcomes for Genetic Testing of 70 Genes in 8565 Patients with Epilepsy and Neurodevelopmental Disorders. Epilepsia 2018, 59, 1062–1071. [Google Scholar] [CrossRef]
  39. Lemke, J.R.; Riesch, E.; Scheurenbrand, T.; Schubach, M.; Wilhelm, C.; Steiner, I.; Hansen, J.; Courage, C.; Gallati, S.; Bürki, S.; et al. Targeted next Generation Sequencing as a Diagnostic Tool in Epileptic Disorders. Epilepsia 2012, 53, 1387–1398. [Google Scholar] [CrossRef]
  40. Møller, R.S.; Larsen, L.H.G.; Johannesen, K.M.; Talvik, I.; Talvik, T.; Vaher, U.; Miranda, M.J.; Farooq, M.; Nielsen, J.E.K.; Lavard Svendsen, L.; et al. Gene Panel Testing in Epileptic Encephalopathies and Familial Epilepsies. Mol. Syndr. 2016, 7, 210–219. [Google Scholar] [CrossRef]
  41. Segal, E.; Pedro, H.; Valdez-Gonzalez, K.; Parisotto, S.; Gliksman, F.; Thompson, S.; Sabri, J.; Fertig, E. Diagnostic Yield of Epilepsy Panels in Children with Medication-Refractory Epilepsy. Pediatr. Neurol. 2016, 64, 66–71. [Google Scholar] [CrossRef] [PubMed]
  42. Butler, K.M.; Da Silva, C.; Alexander, J.J.; Hegde, M.; Escayg, A. Diagnostic Yield From 339 Epilepsy Patients Screened on a Clinical Gene Panel. Pediatr. Neurol. 2017, 77, 61–66. [Google Scholar] [CrossRef] [PubMed]
  43. Miao, P.; Feng, J.; Guo, Y.; Wang, J.; Xu, X.; Wang, Y.; Li, Y.; Gao, L.; Zheng, C.; Cheng, H. Genotype and Phenotype Analysis Using an Epilepsy-associated Gene Panel in Chinese Pediatric Epilepsy Patients. Clin. Genet. 2018, 94, 512–520. [Google Scholar] [CrossRef] [PubMed]
  44. Arafat, A.; Jing, P.; Ma, Y.; Pu, M.; Nan, G.; Fang, H.; Chen, C.; Fei, Y. Unexplained Early Infantile Epileptic Encephalopathy in Han Chinese Children: Next-Generation Sequencing and Phenotype Enriching. Sci. Rep. 2017, 7, 46227. [Google Scholar] [CrossRef]
  45. Leduc-Pessah, H.; White-Brown, A.; Hartley, T.; Pohl, D.; Dyment, D.A. The Benefit of Multigene Panel Testing for the Diagnosis and Management of the Genetic Epilepsies. Genes 2022, 13, 872. [Google Scholar] [CrossRef]
  46. Haviland, I.; Daniels, C.I.; Greene, C.A.; Drew, J.; Love-Nichols, J.A.; Swanson, L.C.; Smith, L.; Nie, D.A.; Benke, T.; Sheidley, B.R.; et al. Genetic Diagnosis Impacts Medical Management for Pediatric Epilepsies. Pediatr. Neurol. 2023, 138, 71–80. [Google Scholar] [CrossRef]
  47. Symonds, J.D.; Zuberi, S.M.; Stewart, K.; McLellan, A.; O’Regan, M.; MacLeod, S.; Jollands, A.; Joss, S.; Kirkpatrick, M.; Brunklaus, A.; et al. Incidence and Phenotypes of Childhood-Onset Genetic Epilepsies: A Prospective Population-Based National Cohort. Brain 2019, 142, 2303–2318. [Google Scholar] [CrossRef]
  48. Peng, J.; Pang, N.; Wang, Y.; Wang, X.; Chen, J.; Xiong, J.; Peng, P.; Zhu, C.; Kessi, M.B.; He, F.; et al. Next-generation Sequencing Improves Treatment Efficacy and Reduces Hospitalization in Children with Drug-resistant Epilepsy. CNS Neurosci. Ther. 2019, 25, 14–20. [Google Scholar] [CrossRef]
  49. Henry, O.J.; Ygberg, S.; Barbaro, M.; Lesko, N.; Karlsson, L.; Peña-Pérez, L.; Båvner, A.; Töhönen, V.; Lindstrand, A.; Stödberg, T.; et al. Clinical Whole Genome Sequencing in Pediatric Epilepsy: Genetic and Phenotypic Spectrum of 733 Individuals. Epilepsia 2025, 66, 2966–2979. [Google Scholar] [CrossRef]
  50. Kim, S.H.; Seo, J.; Kwon, S.S.; Teng, L.; Won, D.; Shin, S.; Lee, J.S.; Lee, S.; Choi, J.R.; Kang, H. Common Genes and Recurrent Causative Variants in 957 Asian Patients with Pediatric Epilepsy. Epilepsia 2024, 65, 766–778. [Google Scholar] [CrossRef]
  51. Boonsimma, P.; Ittiwut, C.; Kamolvisit, W.; Ittiwut, R.; Chetruengchai, W.; Phokaew, C.; Srichonthong, C.; Poonmaksatit, S.; Desudchit, T.; Suphapeetiporn, K.; et al. Exome Sequencing as First-Tier Genetic Testing in Infantile-Onset Pharmacoresistant Epilepsy: Diagnostic Yield and Treatment Impact. Eur. J. Hum. Genet. 2023, 31, 179–187. [Google Scholar] [CrossRef]
  52. Truty, R.; Patil, N.; Sankar, R.; Sullivan, J.; Millichap, J.; Carvill, G.; Entezam, A.; Esplin, E.D.; Fuller, A.; Hogue, M.; et al. Possible Precision Medicine Implications from Genetic Testing Using Combined Detection of Sequence and Intragenic Copy Number Variants in a Large Cohort with Childhood Epilepsy. Epilepsia Open 2019, 4, 397–408. [Google Scholar] [CrossRef]
  53. Liu, J.; Tong, L.; Song, S.; Niu, Y.; Li, J.; Wu, X.; Zhang, J.; Zai, C.C.; Luo, F.; Wu, J.; et al. Novel and de Novo Mutations in Pediatric Refractory Epilepsy. Mol. Brain 2018, 11, 48. [Google Scholar] [CrossRef]
  54. Gaily, E.; Lommi, M.; Lapatto, R.; Lehesjoki, A. Incidence and Outcome of Epilepsy Syndromes with Onset in the First Year of Life: A Retrospective Population-based Study. Epilepsia 2016, 57, 1594–1601. [Google Scholar] [CrossRef] [PubMed]
  55. Balestrini, S.; Sisodiya, S.M. Pharmacogenomics in Epilepsy. Neurosci. Lett. 2018, 667, 27–39. [Google Scholar] [CrossRef]
  56. Borowicz-Reutt, K.; Czernia, J.; Krawczyk, M. Genetic Background of Epilepsy and Antiepileptic Treatments. Int. J. Mol. Sci. 2023, 24, 16280. [Google Scholar] [CrossRef]
  57. Mullagulova, A.I.; Timechko, E.E.; Solovyeva, V.V.; Yakimov, A.M.; Ibrahim, A.; Dmitrenko, D.D.; Sufianov, A.A.; Sufianova, G.Z.; Rizvanov, A.A. Adeno-Associated Viral Vectors in the Treatment of Epilepsy. Int. J. Mol. Sci. 2024, 25, 12081. [Google Scholar] [CrossRef]
  58. Goodspeed, K.; Bailey, R.M.; Prasad, S.; Sadhu, C.; Cardenas, J.A.; Holmay, M.; Bilder, D.A.; Minassian, B.A. Gene Therapy: Novel Approaches to Targeting Monogenic Epilepsies. Front. Neurol. 2022, 13, 805007. [Google Scholar] [CrossRef]
Genes 17 00133 g001aGenes 17 00133 g001b
Figure 1. Proportion of diagnoses achieved through NGS-based genetic testing: (A) Differences in the rate of genetic diagnoses by age of onset, (B) type of genetic test, (C) The contribution of genes to the etiology of epilepsy in the studied cohort, (D) Inheritance patterns, (E) Types of pathogenic or likely pathogenic variants, (F) Proportion of known and novel molecular variants, (G) Genetic etiology profile of epilepsy in pediatric patients.
Figure 1. Proportion of diagnoses achieved through NGS-based genetic testing: (A) Differences in the rate of genetic diagnoses by age of onset, (B) type of genetic test, (C) The contribution of genes to the etiology of epilepsy in the studied cohort, (D) Inheritance patterns, (E) Types of pathogenic or likely pathogenic variants, (F) Proportion of known and novel molecular variants, (G) Genetic etiology profile of epilepsy in pediatric patients.
Genes 17 00133 g001aGenes 17 00133 g001b
Table 1. Clinical characteristics and genotyping of 87 individuals.
Table 1. Clinical characteristics and genotyping of 87 individuals.
Patient IDGenderEpileptic Encephalopathy SuspectedDravet Syndrome SuspectedGeneralized/Focal SeizuresType of SeizuresSeizures OnsetDysmorphismID/Developmental Delay or RegressionMotor DelaySpeech DelayRefractory SeizuresMRI AbnormalitiesEEG AbnormalitiesGenetic Testing MethodGeneGenotype (cDNA)Protein Effecthereditary PatternType of InheritanceGenotype-Fenotype Correlation [OMIM]Classification of Epilepsies Based on Genetic/Molecular Pathomechanism
P01M n/an/an/an/ayesyesn/an/ayesn/aTSO, SangerTUBA1Ac.[920C>T];[=]p.[Pro307Leu];[=]de novoADLIS3DEVELOP
P02Myes n/aTON4 mn/an/an/ayesn/ayesyesTSO, SangerITPAc.[124+1G>A];[124+1G>A]p.[?];[?]biparentalARDEE35DEVELOP
P03FyesyesGEMYOCLON6 mn/an/an/an/ayesn/an/aTSO, SangerSCN1Ac.[3789C>A];[=]p.[Phe1263Leu];[=]n/aADDS/DEE6B/GEFSP2CHANNNEL
P04Fyes n/aTON-CLON1 dn/an/an/an/ayesn/ayesCMHI1000, SangerKCNQ2c.[802C>T];[=]p.[Leu268Phe];[=]de novoADDEE7CHANNNEL
P05F GEn/a2 mn/ayesyesn/an/ayesn/aCMHI1000, SangerCDKL5c.[1675C>T];[=]p.[Arg559*];[=]de novoXLDDEE2DEVELOP
P06Fyes n/aTON-CLON, FEBR, ATONn/an/ayesn/an/ayesyesyesCMHI1000GAMTc.[520T>C];[(520T>C)]p.[Trp174Arg];[=]n/aARCCDS2METAB
P07M yesGEFEBR6 mn/an/an/an/an/an/an/aCMHI1000, SangerSCN1Ac.[2576G>A];[=]p.[Arg859His];[=]maternalADDSCHANNNEL
P08Fyes FEIS, TON-CLON5 dn/ayesyesn/ayesn/ayesWES, SangerGRIN2Ac.[1903G>A];[=]p.[Ala635Thr];[=]de novoADFESDRECEPTOR
P09F yesGEABSEN8 mn/anonon/an/an/an/aCMHI1000, SangerSCN1Ac.[752T>A];[=]p.[Met251Lys];[=]de novoADDSCHANNNEL
P10Fyes GEABSEN, NOC, TON-CLON, MYOCLONn/an/ayesn/ayesn/anoyesCMHI1000, SangerCHD2c.[4797_4798dupCA];[=]p.[Asn1600Thrfs*215];[=]de novoADDEE94DEVELOP
P11M n/aIS, TON, TON-CLON1 dyesn/an/an/ayesyesyesCMHI1000, SangerSCN3Ac.[3998C>T];[=]p.[Pro1333Leu];[=]de novoADDEE62CHANNNEL
P12M yesGEFEBR, TON-CLON8 mn/anononon/an/an/aCMHI1000SCN1Ac.[1177C>T];[=]p.[Arg393Cys];[=]n/aADDSCHANNNEL
P13F FETON, CLON2 mn/ayesyesn/an/an/ayesCMHI1000, SangerSTXBP1c.[1162C>T];[=]p.[Arg388*];[=]de novoADDEE4DEVELOP
P14F n/aIS, MYOCLON5 mn/ayesyesn/ayesnoyesTSOALG13c.[320A>G];[=]p.[Asn107Ser];[=]n/aXLDEE36 (WS)DEVELOP
P15F yesn/aCLON3 yyesyesyesn/an/an/ayesCMHI1000, SangerSYNGAP1c.[333del];[=]p.[Lys114Serfs*20];[=]de novoADMRD5DEVELOP
P16M n/aIS, CLON1 mn/an/an/an/an/ayesn/aTSO, SangerCOL4A1c.[4031G>A];[=]p.[Gly1344Asp];[=]de novoADBSVD1DEVELOP
P17M n/an/an/ayesn/an/an/an/an/an/aCMHI1000, SangerKANSL1c.[808_809del];[=]p.[Leu270Valfs*11];[=]de novoADKDVSDEVELOP
P18M n/an/an/anoyesyesyesyesn/an/aCMHI1000SYNGAP1c.[509G>A];[=]p.[Pro170Argfs*25];[=]n/aADMRD5DEVELOP
P19F yesn/aFEBR, TON-CLON, ABSEN6 mn/an/ayesn/ayesnonoCMHI1000SCN1Ac.[301C>T];[=]p.[Arg101Trp];[=]n/aADDSCHANNNEL
P20Myes MFEMYOCLON, IS4 myesyesyesn/ayesyesyesCMHI1000, SangerSPTAN1c.[6908_6916dup];[=]p.[Asp2303_Leu2305dup];[=]de novoADDEE5DEVELOP
P21F GEn/a13 yn/ayesn/an/an/an/ayesCMHI1000CACNA1Ac.[4252C>T];[=]p.[Arg418*];[=]n/aADDEE42CHANNNEL
P22Myesyesn/aCLON, MYOCLON, NOC, ATON2 dn/an/an/an/an/an/an/aCMHI1000ATP1A3c.[2443G>A];[=]p.[Glu815Lys];[=]n/aADDEE99DEVELOP
P23M GEATON, MYOCLONn/ayesyesn/an/an/anon/aCMHI1000, SangerANKRD11c.[1442C>A];[=]p.[Ser481*];[=]de novoADKBGSDEVELOP
P24Myes GECLON, MYOCLON10 mn/ayesyesn/ayesyesyesCMHI1000, WESWDR45c.[103G>T];[0]p.[Glu35*];[0]de novoXLDNBIA5METAB
P25M n/an/an/ayesn/an/an/an/ayesn/aTSO, SangerPOMT2c.[70del];[70del]p.[Gln24Argfs*41];[Gln24Argfs*41]biparentalARMDDGA2DEVELOP
P26F n/aMULTIPLEn/an/an/an/an/an/an/an/aCMHI1000SCN1Ac.[302G>A];[=]p.[Arg101Gln];[=]n/aADDS/DEE6B/GEFSP2CHANNNEL
P27F n/an/an/an/ayesyesn/ayesn/an/aCMHI1000TPP1c.[622C>T(;)833A>C]p.[Arg208*(;)Gln278Pro]n/aARCLN2METAB
P28Myes GE, FEFEBR18 mn/an/an/an/an/anon/aCMHI1000, SangerSCN1Ac.[4219C>T];[=]p.[Arg1407*];[=]de novoADDS/DEE6B/GEFSP2CHANNNEL
P29Myes FEn/an/an/an/an/an/an/an/an/aCMHI1000SCN2Ac.[781G>T];[=]p.[Val261Leu];[=]n/aADDEE11CHANNNEL
P30Fyes n/an/a2 mn/an/an/an/an/an/ayesCMHI1000, SangerSTXBP1c.[722C>A];[=]p.[Ser241Tyr];[=]de novoADDEE4DEVELOP
P31F n/an/a1 mn/an/an/an/an/an/an/aCMHI1000AMTc.[452_466del];[452_466del]p.[Lys151_Leu155del];[Lys151_Leu155del]n/aARGCEMETAB
P32F GEn/an/an/anonon/an/anoyesCMHI1000PCDH19c.[1145del];[=]p.[Gly382Aspfs*187];[=]n/aXLDEE9DEVELOP
P33F GEFEBR, TON-CLON8 mn/an/an/an/an/an/an/aCMHI1000, SangerSCN1Ac.[2468A>T];[=]p.[Asp823Val];[=]de novoADDS/DEE6B/GEFSP2CHANNNEL
P34F FEABSEN6 yn/ayesyesn/ayesyesn/aCMHI1000, SangerCLN6c.[373A>G];[(373A>G)]p.[Ser125Gly];[Ser125Gly]biparentalARCLNMETAB
P35Fyes n/an/an/an/ayesyesn/ayesn/an/aWESSCN8Ac.[2895C>A];[=]p.[Asn965Lys];[=]de novoADDEE13CHANNNEL
P36Fyes n/an/an/an/ayesn/an/ayesn/an/aTSOSMC1Ac.[3061dup];[=]p.[Ala1021Glyfs*24];[=]de novoXLDDEE85DEVELOP
P37M n/an/a2 dnon/ayesyesn/ayesn/aCMHI1000KCNQ2c.[1678C>T];[=]p.[Arg560Trp];[=]de novoADDEE7CHANNNEL
P38M n/aIS6 dn/ayesyesn/an/anoyesCMHI1000, SangerSTXBP1c.[1162C>T];[=]p.[Arg388*];[=]n/aADDEE4DEVELOP
P39M n/an/a3 yn/ayesn/an/an/an/an/aCMHI1000, SangerSYNGAP1c.[3471G>A];[=]p.[Trp1157*];[=]de novoADMRD5DEVELOP
P40F n/an/a5 yn/ayesnon/an/an/ayesCMHI1000, SangerSLC2A1c.[667C>T];[=]p.[Arg223Trp];[=]paternalADGLUT1DSMETAB
P41F yesn/aFEBR6 mn/an/anon/an/an/an/aCMHI1000, SangerSCN1Ac.[5285G>A];[=]p.[Gly1762Glu];[=]de novoADDSCHANNNEL
P42M n/an/an/an/ayesn/an/an/an/an/aCMHI1000ATP1A2c.[889G>A];[=]p.[Ala297Thr];[=]n/aADFHM2/DEE98DEVELOP
P43F GE, FETON5 myesyesn/an/ayesn/an/aTSO, SangerPCDH19c.[1031C>G];[=]p.[Pro344Arg];[=]paternalXLDEE9DEVELOP
P44F FECLON11 mn/an/an/anoyesnoyesCMHI1000PCDH19c.[1091dup];[=]p.[Tyr366Leufs*10];[=]n/aXLDEE9DEVELOP
P45M n/aMYOCLON, TON-CLON15 yn/an/an/an/an/an/an/aCMHI1000NHLRC1c.[660dup];[(660dup)]p.[Val221Cysfs*13];[(Val221Cysfs*13)]n/aARMELFMETAB
P46F n/an/an/an/an/an/an/an/an/an/aCMHI1000, SangerSLC2A1c.[236G>T];[=]p.[Gly79Val];[=]de novoADGLUT1DSMETAB
P47M GETON, CLON3 yyesn/an/ayesn/ayesn/aCMHI1000, SangerSMARCB1c.[919T>C];[=]p.[Phe307Leu];[=]de novoADCSS3DEVELOP
P48M GE, FECLON10 dn/anonon/an/anoyesCMHI1000ALDH7A1c.[328C>T];[328C>T]p.[Arg110*];[Arg110*]n/aAREPEO4METAB
P49M FECLON, MULTIPLE2 dn/an/an/an/an/an/ayesCMHI1000KCNQ2c.[821C>T];[=]p.[Thr274Met];[=]n/aADDEE7CHANNNEL
P50F n/an/a1 mn/anononon/anon/aTSO, SangerALDH7A1c.[328C>T];[902A>T]p.[Arg110*];[Asn301Ile]biparentalAREPEO4METAB
P51Myes n/aTON, IS3 dn/ayesyesn/ayesn/ayesCMHI1000KCNQ2c.[740C>T];[=]p.[Ser247Leu];[=]n/aADDEE7CHANNNEL
P52M GE, FEn/a12 myesn/anoyesn/an/ayesWES, SangerANKRD11c.[4387_4390del];[=]p.[Glu1463Asnfs*67];[=]de novoADKBGSDEVELOP
P53M n/an/a12 mn/an/ayesyesyesyesyesWES, SangerWDR45c.[235+1G>T];[0]p.[?];[0]de novoXLDNBIA5METAB
P54M FECLONn/an/ayesyesyesyesyesn/aCMHI1000, SangerATP1A2c.[1127C>T];[=]p.[Thr376Met];[=]n/aADDEE98DEVELOP
P55Myes GETON, TON-CLON2 dn/ayesyesn/ayesn/ayesCMHI1000, SangerSCN2Ac.[775C>A];[=]p.[Leu259Ile];[=]de novoADDEE11CHANNNEL
P56M GEIS, TON2 yyesyesyesyesyesyesyesCMHI1000, WES, SangerUBA5c.[796G>C];[1111G>A]p.[Val266Leu];[Ala371Thr]biparentalARDEE44DEVELOP
P57Myes FECLON, TON, MYOCLON2 mn/an/an/an/ayesn/ayesCMHI1000SCN1Ac.[626T>C];[=]p.[Leu209Pro];[=]n/aADDEE6BCHANNNEL
P58F n/aTON, CLON15 dn/an/an/an/an/anoyesCMHI1000KCNQ2c.[1678C>T];[=]p.[Arg560Trp];[=]n/aADDEE7CHANNNEL
P59M yesGEFEBR, CLON, TON2.5 yn/an/an/ayesyesnon/aCMHI1000PCDH19c.[2452C>T];[=]p.[Gln818*];[=]n/aXLDEE9DEVELOP
P60F n/aFEBR2 yyesyesyesyesn/an/an/aCMHI1000ANKRD11c.[7216C>T];[=]p.[Gln2406*];[=]n/aADKBGSDEVELOP
P61F GE, FEABSEN, MYOCLON, TON-CLON6 yyesyesyesn/an/an/an/aCMHI1000ZEB2c.[851G>A];[=]p.[Cys284Tyr];[=]n/aADMOWSDEVELOP
P62F yesn/aTON-CLON, FEBR2 yyesyesyesn/anononoCMHI1000KMT2Ac.[1154del];[=]p.[Lys385Argfs*15];[=]n/aADWDSTSDEVELOP
P63F GEABSEN, FEBR10 mn/anonon/anonon/aCMHI1000GABRG2c.[670C>T];[=]p.[Arg224*];[=]n/aADDEE74RECEPTOR
P64F GEn/a6 mn/an/an/an/an/an/an/aCMHI1000, SangerPRRT2c.[649dup];[=]p.[Arg217Profs*8];[=]n/aADBFIS2DEVELOP
P65Fyes n/an/a1 mn/an/an/an/an/an/an/aCMHI1000KCNQ2c.[436T>C];[=]p.[Trp146Arg];[=]n/aADDEE7CHANNNEL
P66F n/an/an/an/ayesn/ayesn/an/an/aCMHI1000, SangerCHD2c.[693-3C>A];[=]p.[?];[=]de novoADDEE94DEVELOP
P67M GETON-CLON, ATON8 yn/ayesn/an/an/an/an/aCMHI1000STXBP1c.[560C>T];[=]p.[Pro187Leu];[=]n/aADDEE4DEVELOP
P68F n/aTON1 dn/an/an/an/an/an/an/aCMHI1000KCNQ2c.[1955dup];[=]p.[Thr653Aspfs*212];[=]n/aADDEE7CHANNNEL
P69F n/an/a2 yn/an/an/an/an/ayesn/aCMHI1000, WES, SangerUPB1c.[917-1G>A];[917-1G>A]p.[?];[?]biparentalARUPB1DMETAB
P70F GEn/a12 yn/anon/an/an/anon/aWESDEPDC5c.[4674G>A];[=]p.[Trp1558*];[=]n/aADFFEVF1DEVELOP
P71F n/aTON-CLON3 mn/anonon/an/anon/aCMHI1000PRRT2c.[649dup];[=]p.[Arg217Profs*8];[=]n/aADBFIS2DEVELOP
P72F n/aCLON, TON-CLON4 yyesyesyesn/an/ayesyesWESMECP2c.[1115C>A];[=]p.[Ser372*];[=]n/aXLDRTTDEVELOP
P73F yesGETON-CLON6 mn/an/ayesyesn/anoyesCMHI1000SCN1Ac.[5590del];[=]p.[Cys1864Valfs*13];[=]n/aADDSCHANNNEL
P74Myes FECLON2 mn/an/an/an/an/anoyesCMHI1000SCN2Ac.[3956G>C];[=]p.[Arg1319Pro];[=]n/aADDEE11CHANNNEL
P75M n/an/a15 myesyesyesyesn/ayesyesCMHI1000, SangerOPHN1c.[1026-1G>T];[0]p.[?];[0]maternalXLRMRXSBLDEVELOP
P76Myes n/an/an/ayesyesyesyesn/an/an/aTSO, WESUBA5c.[698T>A];[796G>C]p.[Leu233His];[Val266Leu]biparentalARDEE44DEVELOP
P77M n/aABSEN, IS, TON, CLON3 mn/an/anoyesyesyesyesCMHI1000TSC1c.[2228_2229del];[=]p.[Gln743Argfs*10];[=]n/aADTSCDEVELOP
P78M GETON-CLON, CLON, TON, MYOCLON, NOC, IS4.5 yn/ayesyesyesyesn/ayesCMHI1000CHD2c.[2804_2813del];[=]p.[Leu935Trpfs*2];[=]n/aADDEE94DEVELOP
P79F n/aMYOCLON3 yn/ayesyesyesyesn/ayesCMHI1000KCTD7c.[190A>G];[249del]p.[Thr64Ala];[Arg84Glyfs*25]n/aAREPM3 DEVELOP
P80M GEABSEN, ATON, TON-CLON5 yn/ayesn/ayesyesnoyesWESNPC1c.[1274C>A(;)3019C>G]p.[Ser425*(;)Pro1007Ala]n/aARNPCMETAB
P81Myes GEMYOCLON3 mn/an/an/an/an/ayesn/aCMHI1000KCNJ10c.[179T>C];[179T>C]p.[Ile60Thr];[Ile60Thr]n/aARSESAMES CHANNNEL
P82F n/an/an/an/ayesyesyesn/an/an/aCMHI1000CUL3c.[655-1G>A];[=]p.[?];[=]n/aADNEDAUSDEVELOP
P83Fyes n/an/a2 dn/ayesyesn/an/an/an/aCMHI1000, SangerPURAc.[885delinsGC];[=]p.[His296Profs*21];[=]de novoADNEDRIHFDEVELOP
P84Myes n/aMYOCLON, TON3 dn/an/an/an/an/an/ayesCMHI1000KCNQ2c.[619C>T];[=]p.[Arg207Trp];[=]n/aADDEE7DEVELOP
P85M FEABSEN 6 yn/ayesyesyesn/ayesn/aCMHI1000DYNC1H1c.[874C>T];[=]p.[Arg292Trp];[=]n/aADCDCBM13DEVELOP
P86F n/aMYOCLON12 mn/an/an/ayesn/anoyesCMHI1000CHD2c.[3499dup];[=]p.[Val1167Glyfs*9];[=]n/aADDEE94DEVELOP
P87M n/an/an/ayesyesyesyesn/an/an/aCMHI1000, SangerANKRD11c.[6191_6192del];[=]p.(Ser2064Phefs*37)de novoADKBGSDEVELOP
n/a, not available; F, Female; M, Male; CMHI1000, our Institute’s original NGS panel of >1000 genes related to pediatric diseases, TSO, TruSight One panel sequencing; WES, Whole Exome Sequencing; Sanger—Sanger sequencing; GE, generalized epilepsy; FE, focal epilepsy; MFE, multifocal epilepsy; TON, tonic seizures; CLON, clonic seizures; ATON, atonic seizures; MYOCLON, myoclonic seizures; IS, infantile spasm; ABSEN, absence seizures; TON-CLON, tonic–clonic seizures; MYOCLON-ATON, myoclonic–myoclonic–atonic seizures; MYOCLON-TON-CLON, myoclonic-tonic–clonic seizures; FEBR, febrile seizures/during infections; NOC, nocturnal seizures; MULTIPLE, multiple types of seizures, polymorphic seizures.
Table 2. Classification of epilepsies based on genetic/molecular pathomechanism.
Table 2. Classification of epilepsies based on genetic/molecular pathomechanism.
Classification of Epilepsies Based on Genetic/Molecular Pathomechanism
ChannelopathiesReceptoropathiesMetabolic EpilepsyStructural-Genetic/Developmental Epilepsy
Associated genesCACNA1A, KCNJ10, KCNQ2, SCN1A, SCN2A, SCN3A, SCN8AGABRG2, GRIN2AALDH7A1, AMT, CLN6, GAMT, NHLRC1, NPC1, SLC2A1, TPP1, UPB1, WDR45ALG13, ANKRD11, ATP1A2, ATP1A3, CDKL5, CHD2, COL4A1, CUL3, DEPDC5, DYNC1H1, ITPA, KANSL1, KCTD7, KMT2A, MECP2, OPHN1, PCDH19, POMT2, PRRT2, PURA, SMARCB1, SMC1A, SPTAN1, STXBP1, SYNGAP1, TSC1, TUBA1A, UBA5, ZEB2
Number of genes (%)7 (14.6%)2 (4.2%)10 (20.8)29 (60.4%)
Number of patients (%)26 (29.9%)2 (2.3%)13 (14.9%)46 (52.9%)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Chałupczyńska, B.; Ciara, E.; Halat-Wolska, P.; Pollak, A.; Stawiński, P.; Jurkiewicz, D.; Piekutowska-Abramczuk, D.; Gawlik, M.; Pietrasik, J.; Cieślikowska, A.; et al. Molecular Profiling of Polish Pediatric Patients with Epilepsy: A Single-Center Diagnostic Experience Using Next-Generation Sequencing. Genes 2026, 17, 133. https://doi.org/10.3390/genes17020133

AMA Style

Chałupczyńska B, Ciara E, Halat-Wolska P, Pollak A, Stawiński P, Jurkiewicz D, Piekutowska-Abramczuk D, Gawlik M, Pietrasik J, Cieślikowska A, et al. Molecular Profiling of Polish Pediatric Patients with Epilepsy: A Single-Center Diagnostic Experience Using Next-Generation Sequencing. Genes. 2026; 17(2):133. https://doi.org/10.3390/genes17020133

Chicago/Turabian Style

Chałupczyńska, Beata, Elżbieta Ciara, Paulina Halat-Wolska, Agnieszka Pollak, Piotr Stawiński, Dorota Jurkiewicz, Dorota Piekutowska-Abramczuk, Marzena Gawlik, Justyna Pietrasik, Agata Cieślikowska, and et al. 2026. "Molecular Profiling of Polish Pediatric Patients with Epilepsy: A Single-Center Diagnostic Experience Using Next-Generation Sequencing" Genes 17, no. 2: 133. https://doi.org/10.3390/genes17020133

APA Style

Chałupczyńska, B., Ciara, E., Halat-Wolska, P., Pollak, A., Stawiński, P., Jurkiewicz, D., Piekutowska-Abramczuk, D., Gawlik, M., Pietrasik, J., Cieślikowska, A., Wicher, D., Ulatowska, A., Jedlińska, D., Borkowska, J., Chmielewski, D., Dunin-Wąsowicz, D., Kotulska-Jóźwiak, K., Chrzanowska, K., & Madej-Pilarczyk, A. (2026). Molecular Profiling of Polish Pediatric Patients with Epilepsy: A Single-Center Diagnostic Experience Using Next-Generation Sequencing. Genes, 17(2), 133. https://doi.org/10.3390/genes17020133

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop